TARRIFF SCOTT (CEO) sold 2.7% of their position (45K shares) of EAGLE PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $930.7K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 5 sales
Filed: 5/15/2023ACC: 0001209191-23-029625
DirectorOfficer· CEO
Since Jun 2018
-45K
Net shares
Net seller
$930.7K
Total sold
5
Open market trades
0B · 5S
5
Total transactions
45K disposed
Non-Derivative Transactions5
Common Stock
Direct
Shares
−15K
Price / share
$20.71
Trade value
$310.65K
% of position
0.9%
5/11/2023
1.64M→1.62M
Common Stock
Direct
Shares
−3.13K
Price / share
$19.69
Trade value
$61.65K
% of position
0.2%
5/12/2023
1.62M→1.62M
Common Stock
Direct
Shares
−11.87K
Price / share
$20.42
Trade value
$242.36K
% of position
0.7%
5/12/2023
1.62M→1.61M
Common Stock
Direct
Shares
−14.80K
Price / share
$21.06
Trade value
$311.69K
% of position
0.9%
5/15/2023
1.61M→1.60M
Common Stock
Direct
Shares
−200.00
Price / share
$21.52
Trade value
$4.30K
% of position
0.0%
5/15/2023
1.60M→1.59M
Total
Net shares
−45K
Net value
-$930.66K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/11/2023 | S · Sale | −15K | $20.71 | $310.65K | 0.9% | 1.64M | 1.62M |
| Common Stock Direct | 5/12/2023 | S · Sale | −3.13K | $19.69 | $61.65K | 0.2% | 1.62M | 1.62M |
| Common Stock Direct | 5/12/2023 | S · Sale | −11.87K | $20.42 | $242.36K | 0.7% | 1.62M | 1.61M |
| Common Stock Direct | 5/15/2023 | S · Sale | −14.80K | $21.06 | $311.69K | 0.9% | 1.61M | 1.60M |
| Common Stock Direct | 5/15/2023 | S · Sale | −200.00 | $21.52 | $4.30K | 0.0% | 1.60M | 1.59M |
| Total | −45K | -$930.66K | ||||||
Derivative Transactions0
No derivative transactions reported